Bayer Pulls Aliqopa Combo Filings In EU, US & Other Markets – But May Resubmit
Executive Summary
The company plans to conduct additional analyses of data from ongoing trials that are testing its PI3K inhibitor in combination with rituximab for treating types of indolent B-cell non-Hodgkin’s lymphoma.